TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Ltd announced a change in the director’s interest, with Mr. Marc Voigt acquiring 1,200,000 fully paid ordinary shares through the vesting and exercise of performance rights. This change reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting investor confidence and market perception positively.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company specializes in leveraging the LAG-3 immune control mechanism to create innovative therapies that enhance the body’s immune response against diseases.
Average Trading Volume: 2,480,709
Technical Sentiment Signal: Hold
Current Market Cap: A$426.9M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.